Case Report: Efficacy of Disitamab Vedotin (RC-48) in HER2-Low Metastatic Breast Cancer

A 296.0 KB case report document details the treatment of a 40-year-old woman with heavily pretreated HER2-low metastatic breast cancer using the antibody-drug conjugate disitamab vedotin (RC-48). The report, authored by Ruiyue Wu and shared under a CC-BY-4.0 license on figshare, describes a time to treatment failure of 4.6 months and overall survival of 13.7 months post-treatment initiation.

Use Cases

• Analyzing clinical response patterns based on the reported tumor marker improvement and lesion regression.
• Studying the dynamics of HER2 status evolution based on the described changes from diagnosis through metastasis.
• Evaluating time-to-treatment-failure outcomes for later-line therapies based on the reported 4.6-month TTF.
• Investigating the role of repeat biopsy in treatment planning based on the case's emphasis on reassessment.

Strengths

• Provides detailed clinical timeline including a 4.6-month time to treatment failure and 13.7-month survival period.
• Focuses on a specific and emerging therapeutic subgroup (HER2-low metastatic breast cancer).
• Document is openly shared under a permissive CC-BY-4.0 license.

Limitations

• Row count is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.
• Data is a single case report (296.0 KB), representing a very limited sample size.

Provenance

Source

figshare

Collection Method

Clinical case documentation.

Time Range

Covers the treatment and follow-up period for a single patient case.

Freshness

Last updated 2026-05-04 04:16:48; freshness should be verified.

Geography

Likely involves a patient from China, given the focus on the first China-developed ADC.